|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 193.7 USD | -0.23% |
|
-0.78% | -25.17% |
| 12:00pm | Alzheimer's drug adoption in US slowed by doctors' skepticism | RE |
| Apr. 19 | Needham Adjusts Price Target on Biogen to $294 From $300 | MT |
Oct 17 (Reuters) - Biogen Inc said on Monday the U.S. Food and Drug Administration had extended the review of its experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS) by three months.
The company said the new target action date provided by the agency is April 25, 2023. (Reporting by Bhanvi Satija in Bengaluru; Editing by Devika Syamnath)
| 1st Jan change | Capi. | |
|---|---|---|
| -25.17% | 28.22B | |
| -2.68% | 85.68B | |
| +4.08% | 41.4B | |
| +54.31% | 24.64B | |
| -4.68% | 16.98B | |
| -42.09% | 13.29B | |
| -17.27% | 11.66B | |
| -12.10% | 11.65B | |
| +0.75% | 8.18B | |
| +5.07% | 7.78B |
BIOGEN INC. 
